

**VIROTECH HSV 1 (gG1) IgG/IgM ELISA
(HSV 1 (gG1) IgG/IgM ELISA)**

Order No.: EC130.00 Color Coding: red/black

HSV 1 (gG1) IgG Liquor/CSF Standards

Order No.: EC130L60

**VIROTECH HSV 2 (gG2) IgG/IgM ELISA
(HSV 2 (gG2) IgG/IgM ELISA)**

Order No.: EC131.00 Color Coding: red/dark blue

HSV 2 (gG2) IgG Liquor/CSF Standards

Order No.: EC131L60

FOR IN VITRO DIAGNOSIS ONLY

**Virotech Diagnostics GmbH
Waldstrasse 23 A2
63128 Dietzenbach, Germany**

**Tel.: +49(0)6074-23698-0
Fax.: +49(0)6074-23698-900
www.goldstandarddiagnostics.com**



Contents

1. Intended Use.....	3
2. Diagnostic Relevance	3
3. Test Principle.....	4
4. Package Contents (IgG and IgM Testkit)	4
5. Storage and Shelflife of the Testkit and the ready to use reagents	4
6. Precautions and Warnings.....	5
7. Material required but not supplied	5
8. Test Procedure	5
8.1 Examination Material.....	5
8.2 Preparation of Reagents	5
8.3 VIROTECH ELISA Test Procedure	6
8.4 Usage of ELISA processors	6
9. Test Evaluation.....	6
9.1 Test function control.....	6
9.2 Calculation of the VIROTECH Units (VE)	7
9.3 Interpretation Scheme IgG and IgM	7
9.4 Limits of the Test.....	7
10. Performance Data	7
10.1 Diagnostic sensitivity (Positive Percent Agreement) and specificity (Negative Percent Agreement).....	7
10.2 Prevalence of infection (expected values)	9
10.3 Interfering substances.....	9
10.4 Cross-reactivity	10
10.5 Measuring range	11
10.6 Intra-assay variation coefficient (repeatability).....	11
10.7 Within-run variation coefficient (reproducibility)	12
11. Literature.....	12
12. Test Procedure Scheme	13

1. Intended Use

The VIROTECH HSV 1 (gG1) IgG/IgM ELISA resp. the VIROTECH HSV 2 (gG2) IgG/IgM ELISA is intended for the semiquantitative and qualitative detection of specific IgG/IgM -antibodies against *Herpes simplex Virus* (HSV) type 1 resp. type 2 in human serum.

The serology is suitable for the detection of the immune status and as Herpes exclusion. The use of the type-specific glycoproteins G, gG1 and gG2 allows differentiation between HSV 1 and HSV 2 for the determination of seroprevalence and for the identification of potential virus carriers.

The IgM result must not be observed isolated from the IgG result.

The diagnosis of the genital-herpes must be confirmed with the pathogen detection.

The serology is not suitable for the detection of new-born Herpes, as the immune system of a baby is not completely developed at the date of its birth. However, it can be used in retrospect to measure the transplacentally transferred anti-HSV-2 IgG-antibodies.

2. Diagnostic Relevance

Herpes simplex viruses have a high prevalence of infection in the population as they are transmitted via the mucous membranes through close physical contact. The first infection with HSV-1 most often occurs during childhood after the loss of maternal protection within the first year of life. HSV-2 is mainly transmitted through sexual intercourse; accordingly, infection rates only increase with puberty (16).

However these primary infections remain asymptomatic in over 90% of the cases, a latent infection is established in the regional ganglia as a rule. For the understanding of the pathogenesis of HSV-infection the fact that latent persistent viruses in the ganglia cells may be reactivated is of important meaning. The further spreading of the virus is favoured by the asymptomatic virus expression throughout saliva and genital secretion. In the orofacial area the HSV1-infections prevail, whereas in the genital area the infections are mostly caused by HSV 2. Only a small part (5-30%) is generated by HSV 1 (11, 14).

One of the most serious consequences of genital herpes is neonatal herpes (2). Without therapy, mortality for untreated infants who develop disseminated infection exceeds 70% with half of the survivors developing neurological impairment (14). Almost all neonate HSV 2 infections are acquired by passage through an infected birth canal (7). Most mothers (60-80%) who transmit HSV to their children are asymptomatic at delivery (14). Transmission rates are much higher when the mother is experiencing a primary or initial genital infection (50%) (14) versus a recurrent infection (<5%) (4, 5, 9). CDC recommends that „...*prevention of neonatal herpes should emphasize the prevention of acquisition of genital HSV infection during late pregnancy. Susceptible women whose partners have oral or genital HSV infection, or those whose sex partners infection status is unknown, should be counseled to avoid unprotected genital and oral sexual contact during late pregnancy*“ (7).

Viral isolation, direct fluorescent antibody (DFA) testing, and serology can be used to diagnose HSV infections. Disadvantages of the first two methods are however, length of culture time, specimen collection and transport difficulties, procedural complexity, and other variables that are associated with DFA and culture (1, 7). However, due to the significant cross-reactivity between HSV 1 and HSV 2, the serological assays, that use virus lysates as antigens, are not sufficiently suited to differentiate HSV 1 infections from HSV 2 infections. Due to the high contamination with HSV 1, the serological status for HSV 2 can be detected hardly reliable with such methods (14).

Intrathecal IgG-antibodies occur only 8 – 10 days after the clinical symptoms in a present Herpes encephalitis. IgM antibodies are not regularly developed, but if so, it is in short term appearance and in very low concentration. This means the serology can be used as a confirmatory tool of the clinical diagnosis retroactively.

The genital HSV 1-infections recurrent considerably more rarely than HSV 2-infections. A previous infection with genital HSV1 seems to give a certain protection of infections with HSV 2 respectively allays the symptoms or entirely prevent them (10). A previous oral HSV 1 infection does not protect against a genital HSV 2 infection (14). The clinical picture of genital herpes corresponds those of other ulceration of the sexual organs and has therefore to be differentiated against *Haemophilus durcreyi*, *Treponema pallidum* and *Chlamydia trachomatis* (7).

Herpes simplex CSF diagnosis

In contrast to the serological diagnosis of HSV infections, what is most important in CSF diagnosis is the reliable detection of endogenous synthesis of pathogen-specific antibodies in the CNS, rather than any differentiation between the pathogen species HSV-1 and HSV-2. As a result of the combination of highly purified HSV-1 and HSV-2 lysate antigens in the VT HSV screening test, this test system provides a very suitable screening test for the CSF diagnosis of HSV infections of the CNS, as it is highly sensitive. A broad spectrum of highly purified HSV antigens is used in the VT-HSV screen. This not only leads to the desired high sensitivity, but also to the equally desirable specificity with respect to differentiation from CNS infections with other neurotropic pathogens of the herpes virus group.

We therefore recommend that the antibody index (AI) should initially be determined in Herpes simplex diagnostic testing with the HSV Screen ELISA.

If there is the additional aim of achieving differentiation between HSV1 and HSV2 after detection of an HSV-CNS infection, this can be achieved with the help of the two species-specific gG1 and gG2 ELISA tests.

Limits: The level of pathogen-specific antibodies against the gG1 or gG2 epitopes in the CNS at the time when the CSF sample is taken may still (or already) be too low to increase the AI. Therefore, if the gG1 or gG2 test is performed alone this may give a false negative result in some cases or in specific cases, meaning that the antibody index is neither not calculable, or is normal.

3. Test Principle

The antibody searched for in the human serum forms an immune complex with the antigen coated on the microtiter-plate. Unbound immunoglobulins are removed by washing processes. The enzyme conjugate attaches to this complex. Unbound conjugate is again removed by washing processes. After adding the substrate solution (TMB), a blue dye is produced by the bound enzyme (peroxidase). The color changes to yellow when the stopping solution is added.

4. Package Contents (IgG and IgM Testkit)

1. **1 Microtiter-Plate** consisting of 96 with antigen coated, breakable single wells, lyophilised
2. **PBS-Dilution Buffer (blue, ready to use) 2x50ml**, pH 7,2, with preservative and Tween 20
3. **PBS-Washing Solution (20x concentrated) 50ml**, pH 7,2, with preservative and Tween 20
4. **IgG negative Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
5. **IgG cut-off Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
6. **IgG positive Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
7. **IgM negative Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
8. **IgM cut-off Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
9. **IgM positive Control, 1300µl**, human serum with protein-stabilizer and preservative, ready to use
10. **IgG-Conjugate (anti-human), 11ml**, (sheep or goat)-horseradish-peroxidase-conjugate with protein-stabilizer and preservative in Tris-Buffer, ready to use
11. **IgM-Conjugate (anti-human), 11ml**, (sheep or goat)-horseradish-peroxidase-conjugate with FCS and preservative in Tris-Buffer, ready to use
12. **Tetramethylbenzidine substrate solution (3,3',5,5'-TMB), 11ml**, ready to use
13. **Citrate-Stopping Solution, 6ml**, contains an acid mixture

5. Storage and Shelflife of the Testkit and the ready to use reagents

Store the testkit at 2-8°C. The shelf life of all components is shown on each respective label; for the kit shelf life please see Quality Control Certificate.

1. Microtiter strips/single wells are to be resealed in package after taking out single wells and stored with desiccant at 2-8°C. Reagents should immediately be returned to storage at 2-8°C after usage.
2. The ready to use conjugate and the TMB-substrate solution are sensitive to light and have to be stored in dark. Should there be a color reaction of the substrate dilution due to incidence of light, it is not useable anymore.
3. Take out only the amount of ready to use conjugate or TMB needed for the test insertion. Additional conjugate or TMB taken out may not be returned but must be dismissed.

Material	Status	Storage	Shelflife
----------	--------	---------	-----------

Test Samples	Diluted	+2 to +8°C	max. 6h
	Undiluted	+2 to +8°C	1 week
Controls	After Opening	+2 to +8°C	3 months
Microplate	After Opening	+2 to +8° (storage in the provided bag with desiccant bag)	3 months
RF-SorboTech	Undiluted, After Opening	+2 to +8°C	3 months
	Diluted	+2 to +8°C	1 week
Conjugate	After Opening	+2 to +8°C (protect from light)	3 months
Tetramethylbenzidine	After Opening	+2 to +8°C (protect from light)	3 months
Stop Solution	After Opening	+2 to +8°C	3 months
Washing Solution	After Opening	+2 to +8°C	3 months
	Final Dilution (ready-to-use)	+2 to +25°C	4 weeks

6. Precautions and Warnings

- Only sera which have been tested and found to be negative for HIV-1 antibodies, HIV-2 antibodies, HCV antibodies and Hepatitis-B surface-antigen are used as control sera. Nevertheless, samples, diluted samples, controls, conjugates and microtiter strips should be treated as potentially infectious material. Please handle products in accordance with laboratory directions.
- Those components that contain preservatives, the Citrate Stopping Solution and the TMB have an irritating effect to skin, eyes and mucous. If body parts are contacted, immediately wash them under flowing water and possibly consult a doctor.
- The disposal of the used materials has to be done according to the country-specific guidelines.

7. Material required but not supplied

- Aqua dest./demin.
- Eight-channel pipette 50µl, 100µl
- Micropipettes: 10µl, 100µl, 1000µl
- Test tubes
- Paper towels or absorbent paper
- Cover for ELISA-plates
- Disposal box for infectious material
- ELISA handwasher or automated EIA plate washing device
- ELISA plate spectrophotometer, wavelength = 450nm, reference length = 620nm (Reference Wavelength 620-690nm)
- Incubator

8. Test Procedure

Working exactly referring to the VIROTECH Diagnostics user manual is the prerequisite for obtaining correct results.

8.1 Examination Material

Either serum or plasma can be used as test material, even if only serum is mentioned in the instructions. Any type of anticoagulant can be used for plasma.

Always prepare patient-dilution freshly.

For a longer storage the sera must be frozen. Repeated defrosting should be avoided.

- Only fresh non-inactivated sera should be used.
- Hyperlipaemic, haemolytic, microbially contaminated and turbid sera should not to be used (false positive/negative results).

8.2 Preparation of Reagents

The VIROTECH Diagnostics System Diagnostica offers a high degree of flexibility regarding the possibility to use the dilution buffer, washing solution, TMB, citrate stopping solution as well as the conjugate for all parameters and for all different lots. The ready to use controls (positive control, negative control, cut-off control) are **parameter specific** and **only to use** with the plate lot indicated in the Quality Control Certificate.

- Set incubator to 37°C and check proper temperature setting before start of incubation.
- Bring all reagents to room temperature before opening package of microtiter strips.

3. Shake all liquid components well before use.
4. Make up the washing solution concentrate to 1 L with distilled or demineralised water. If crystals have formed in the concentrate, please bring the concentrate to room temperature before use and shake well before use.
5. High IgG-titer or rheumatoid factors may disturb the specific detection of IgM-antibodies and may lead to false positive resp. false negative results. **For a correct IgM-determination it is therefore necessary to pre-treat the sera with RF-SorboTech** (VIROTECH adsorbent). For IgM-controls a pre-absorbent treatment is not necessary.

8.3 VIROTECH ELISA Test Procedure

1. For each test run, pipette 100µl each of ready to use dilution buffer (blank), IgG- and IgM-positive, negative and cut-off controls as well as diluted patient sera. We propose a double insertion (blank, controls and patient sera); for cut-off control a double insertion is absolutely necessary. Working dilution of patient sera: 1+100; e.g. 10µl serum + 1ml dilution buffer.
2. After pipetting start incubation for 30 min. at 37°C (with cover).
3. End incubation period by washing microtiter strips 4 times with 350 – 400µl washing solution per well. Do not leave any washing solution in the wells. Remove residues on a cellulose pad.
4. Pipette 100µl of ready to use conjugate into each well.
5. Incubation of conjugates: 30 min. at 37°C (with cover).
6. Stop conjugate incubation by washing 4 times (pls. refer to point 3 above).
7. Pipette 100µl of ready to use TMB into each well.
8. Incubation of substrate solution: 30 min. at 37°C (with cover, keep in dark).
9. Stopping of substrate reaction: pipette 50µl of citrate stopping solution into each well. Shake plate carefully and thoroughly until liquid is completely mixed and a homogeneous yellow color is visible.
10. Measure extinction (OD) at 450/620nm (Reference Wavelength 620-690nm). Set your photometer in such a way that the blank value is deducted from all other extinctions. Extinctions should be measured within 1 hour after adding the stopping solution!

Pls. refer to last page for Test Procedure Scheme

8.4 Usage of ELISA processors

All VIROTECH Diagnostics ELISAs can be used on ELISA processors. The user is bound to proceed a validation of the devices (processors) on a regular basis.

VIROTECH Diagnostics recommends the following procedure:

1. VIROTECH Diagnostics recommends proceeding the validation of device referring to the instructions of the device manufacturer during the implementation of the ELISA processor respectively after bigger reparations.
2. It is recommended to check the ELISA-processor with the Validationkit (EC250.00) afterwards. A regular check using the Validationkit shall be proceeded minimum once a quarter to test the accuracy of the processor.
3. The release criteria of the Quality Control Certificate of the product must be fulfilled for each test run.

With this procedure, your ELISA processor will function properly, and this will support quality assurance in your laboratory.

9. Test Evaluation

The ready to use controls serve for a semiquantitative determination of specific IgG- and IgM-antibodies. Their concentration can be expressed in VIROTECH units = VE. Fluctuations resulting from the test procedure can be balanced with this calculation method and a high reproducibility is achieved in this way. Use the means of the OD values for calculation of the VE.

9.1 Test function control

a) OD-values

The OD of the blank should be < 0.15.

The OD-values of the negative controls should be lower than the OD-values mentioned in the Quality Control Certificate. The OD-values of the positive controls as well as of the cut-off controls should be above the OD-values mentioned in the Quality Control Certificate.

b) VIROTECH Units (VE)

The VIROTECH Units (VE) of the cut-off controls are defined as 10 VE. The calculated VE of the positive controls should be within the ranges mentioned in the Quality Control Certificate.

If those requirements (OD-values, VE) are not fulfilled, the test must be repeated.

9.2 Calculation of the VIROTECH Units (VE)

The extinction of the blank value (450/620nm) must be subtracted from all other extinctions.

$$\begin{aligned} \text{VE (positive control)} &= \frac{\text{OD (positive control)}}{\text{OD (cut-off control)}} \times 10 \\ \text{VE (patient serum)} &= \frac{\text{OD (patient serum)}}{\text{OD (cut-off control)}} \times 10 \end{aligned}$$

9.3 Interpretation Scheme IgG and IgM

Result (VE)	Evaluation
< 9,0	negative
9,0 - 11,0	borderline
> 11,0	positive

1. If the measured values are above the defined borderline range, they are positive.
2. If the measured VE is within the borderline range, no significant high antibody concentration is present, the samples are borderline. For the secure detection of an infection, it is necessary to determine the antibody concentration of two serum samples. One sample shall be taken directly at the beginning of the infection and a second sample 5 – 10 days later (convalescent serum). The antibody concentration of both samples has to be tested in parallel, that means in one test run. A correct diagnosis based on the evaluation of a single serum sample is not possible.
3. If the measured values are below the defined borderline range, no measurable antigen specific antibodies are present in the samples. The samples are negative.
4. In case of a positive IgM result a verification of the result with PCR is recommended.

9.4 Limits of the Test

6. The interpretation of serological results shall always include the clinical picture, epidemiological data, and all further available laboratory results.
7. Despite all advantages of the gG2-assay there exist also notes towards the limits of the test: On one hand the therapy with Acyclovir may influence the antibody development (3) and on the other hand, the genetic variability of the gG2 protein may lead to gG2 negative HSV 2 strains.

10. Performance Data

10.1 Diagnostic sensitivity (Positive Percent Agreement) and specificity (Negative Percent Agreement)

HSV 1 (gG1) IgG

To determine the diagnostic sensitivity and specificity, 92 sera were tested in the VIROTECH HSV 1 (gG1) IgG ELISA and a reference test.

VIROTECH HSV 1 (gG1) IgG ELISA	Reference test			
	negative	borderline	positive	Total
negative	23	8	1	32
borderline	1	6	0	7
positive	0	2	51	53
Total	24	16	52	92

The borderline sera were not taken into account when calculating the sensitivity and specificity.

Sensitivity/PPA = 98%

Specificity/NPA = 100%

HSV 1 (gG1) IgM

To determine the diagnostic sensitivity and specificity, 88 sera were tested in the VIROTECH HSV 1 (gG1) IgM ELISA and a reference test.

VIROTECH HSV 1 (gG1) IgM ELISA	Reference test			
	negative	borderline	positive	Total
negative	52	5	14	71
borderline	1	0	1	2
positive	2	1	12	15
Total	55	6	27	88

The borderline sera were not taken into account when calculating the sensitivity and specificity.

Sensitivity/PPA = 46%

Specificity/NPA = 96%

7 sera showed a discrepancy in results between the VIROTECH HSV 1 (gG1) IgG/IgM ELISA and the reference test. These sera were then determined again in a second reference test. Of these 7 discrepant sera, 5 sera showed an identical negative result with the VIROTECH HSV 1 (gG1) IgG/IgM ELISA, and 2 sera showed a borderline result.

HSV 2 (gG2) IgG

To determine the diagnostic sensitivity and specificity, 88 sera were tested in the VIROTECH HSV 2 (gG2) IgG ELISA and a reference test.

VIROTECH HSV 2 (gG2) IgG ELISA	Reference test			
	negative	borderline	positive	Total
negative	58	0	0	58
borderline	6	3	1	10
positive	3	4	13	20
Total	67	7	14	88

The borderline sera were not considered when calculating the sensitivity and specificity.

Sensitivity/PPA = 100%

Specificity/NPA = 95%

HSV 2 (gG2) IgM

To determine the diagnostic sensitivity and specificity, 88 sera were tested in the VIROTECH HSV 2 (gG2) IgM ELISA and a reference test.

VIROTECH HSV 2 (gG2) IgM ELISA	Reference test			
	negative	borderline	positive	Total
negative	72	0	1	73
borderline	2	0	3	5

positive	4	0	6	10
Total	78	0	10	88

The borderline sera were not considered when calculating the sensitivity and specificity.

Sensitivity/PPA = 86%

Specificity/NPA = 95%

10.2 Prevalence of infection (expected values)

HSV 1 (gG1)

IgG/IgM

To determine the 70% prevalence of infection in IgG and 0% prevalence of infection in IgM in adults as described in the literature (15), 78 blood donor sera (blood donor panel Frankfurt a.M., Hesse) were tested.

Sera collective (n=78)	VIROTECH HSV 1 (gG1) IgG/IgM ELISA	
	IgG	IgM
Positive	55	1
Borderline	5	2
Negative	18	75
Prevalence of infection in %	70.5	1.3

HSV 2 (gG2)

IgG/IgM

To determine the 9.6% prevalence of infection in IgG and 0% prevalence of infection in IgM in adults as described in the literature (8), 80 blood donor sera (blood donor panel Frankfurt a.M., Hesse) were tested.

Sera collective (n=80)	VIROTECH HSV 2 (gG2) IgG/IgM ELISA	
	IgG	IgM
Positive	3	2
Borderline	0	0
Negative	77	78
Prevalence of infection in %	3.8	2.5

10.3 Interfering substances

HSV 1 (gG1)

IgG/IgM

Pathological values of haemoglobin, bilirubin, cholesterol, and triglycerides have no influence on the performance of VIROTECH HSV1 (gG1) IgG/IgM ELISA.

HSV 2 (gG2)

IgG/IgM

Pathological values of haemoglobin, bilirubin, cholesterol, and triglycerides have no influence on the performance of VIROTECH HSV2 (gG2) IgG/IgM ELISA.

10.4 Cross-reactivity

a) HSV 1 (gG1)

IgG: To determine the cross-reactivity of the VIROTECH HSV 1 (gG1) ELISA in IgG, 200 pre-characterized patient sera were tested that were positive for one of the pathogens listed in the table. Sera that tested positive in the VIROTECH HSV 1 (gG1) ELISA were additionally tested with an ELISA of another supplier of tests.

Pathogen	Number tested	neg	equ	pos	Positive result confirmed on competitor device
Candida albicans	12	0	0	12	Yes
Chlamydia trachomatis	10	3	1	6	Partial
CMV	15	2	0	13	Partial
EBV	15	3	1	11	Yes
HPV	7	1	0	6	Partial
HSV-2	9	3	0	6	Yes
Masern Virus	15	4	1	10	Yes
Parainfluenza Virus	15	3	1	11	Yes
Rubella Virus	14	2	0	12	Partial
Toxoplasma gondii	13	3	0	10	Partial
Treponema pallidum	15	0	0	15	Partial
VZV	15	4	1	10	Yes
Anti Nuclear Antibodies	15	0	1	14	Partial
Pregnancy	15	3	0	12	Partial
Rheumatoid factor	15	3	0	12	Partial

Due to lack of sample material, a possible cross-reaction with the pathogen Neisseria gonorrhea could not be verified.

IgM: To determine the cross-reactivity of the VIROTECH HSV 1 (gG1) ELISA in IgM, 163 pre-characterized patient sera were tested that were positive for one of the pathogens listed in the table. Sera that tested positive in the VIROTECH HSV 1 (gG1) ELISA were additionally tested with an ELISA of another supplier of tests.

Pathogen	Number tested	neg	equ	pos	Positive result confirmed on competitor device
Candida albicans	15	10	2	3	No
Chlamydia trachomatis	8	5	1	2	No
CMV	15	13	0	2	Partial
EBV	15	5	2	8	Partial
HSV-2	5	4	1	0	Partial
Masern Virus	14	11	1	2	No
Parainfluenza Virus	9	9	0	0	Partial
Rubella Virus	4	4	0	0	Partial
Toxoplasma gondii	11	8	0	3	No
Treponema pallidum	15	12	1	2	No
VZV	7	5	0	2	Partial
Anti Nuclear Antibodies	15	14	1	0	Partial
Pregnancy	15	14	0	1	Yes
Rheumatoid factor	15	15	0	0	Partial

Due to lack of sample material, a possible cross-reaction with the pathogen Neisseria gonorrhea could not be verified.

b) HSV 2 (gG2)

IgG: To determine the cross-reactivity of the VIROTECH HSV 2 (gG2) ELISA in IgG, 34 precharacterized patient sera positive for one of the pathogens listed in the table were tested.

Pathogen	Number tested	neg	equ	pos
VZV	5	4	1	0
Masern Virus	8	8	0	0
CMV	10	10	0	0
EBV	9	9	0	0
Parvovirus	2	2	0	0

In the VIROTECH HSV 2 (gG2) ELISA, none of the sera tested is IgG positive.

IgM: To determine the cross-reactivity of the VIROTECH HSV 2 (gG2) ELISA in IgM, 22 pre-characterized patient sera positive for one of the pathogens listed in the table were tested.

Pathogen	Number tested	neg	equ	pos
VZV	5	4	1	0
Masern Virus	4	3	1	0
CMV	6	4	0	2
EBV	5	5	0	0
Parvovirus	2	2	0	0

IgM: In the VIROTECH HSV 2 (gG2) ELISA 2 CMV sera are IgM positive.

10.5 Measuring range

a) VIROTECH HSV 1 (gG1) IgG/IgM ELISA

10.5.1 Limit of Blank (LoB)

For the calculation of the LoB according to the CLSI Guideline EP17-A2 a total of 4 negative sera were tested on 2 batches over 5 days in triple determination.

The determined LoB for IgG gives an OD value of 0.078.

The determined LoB for IgM gives an OD value of 0.054.

10.5.2 Limit of Detection (LoD)

For the calculation of the LoD according to the CLSI Guideline EP17-A2, a total of 4 low positive sera were tested over 4 days on 2 batches in quadruple determination.

The determined LoD for IgG gives an OD value of 0.086.

The determined LoD for IgM gives an OD value of 0.070.

b) VIROTECH HSV 2 (gG2) IgG/IgM ELISA

n/a

10.6 Intra-assay variation coefficient (repeatability)

HSV 1 (gG1)

Strips of different plates of one batch were tested with 2 sera in an assay using the checkerboard method. The thus determined coefficient of variation for HSV 1 (gG1) is < 12%.

HSV 2 (gG2)

Strips of different plates of one batch were tested with 2 sera in an assay using the checkerboard method. The thus determined coefficient of variation for HSV 2 (gG2) is < 15%.

10.7 Within-run variation coefficient (reproducibility)

HSV 1 (gG1)

For the determination of the comparative precision, 10 sera from 3 persons on 3 different days were evaluated and the VC of the VE values were considered. The thus determined coefficient of variation for HSV 1 (gG1) is $\leq 20\%$.

HSV 2 (gG2)

For the determination of the comparative precision, 7 sera from 3 persons on 3 different days were evaluated and the VC of the VE values were considered. The thus determined coefficient of variation for HSV 2 (gG2) is $\leq 20\%$.

11. Literature

1. Anzivino, E, D Fioriti, M Mischitelli, A Bellizzi, V Barucca, F Chiarini, V Pietropaolo. 2009. Herpes simplex virus infection in pregnancy and in neonate: status of art of epidemiology, diagnosis, therapy and prevention. *Virol J.* 6,40
2. Arvin, A, C Prober. 1995. Herpes Simplex Viruses. 876-883. In Murray, P, E Baron, M Pfaller, F Tenover, and R Tenover (eds.). *Manual of Clinical Microbiology*. 6th Ed. ASM, Washington, D.C.
3. Bernstein, DI, LR Stanberry, CJ Harrison, JC Kappes, MG Myers. 1986. Antibody response, recurrence patterns and subsequent herpes simplex virus type 2 (HSV-2) re-infection following initial HSV-2 infection of guinea-pigs: effects of acyclovir. *J Gen Virol.* 67, 1601-1612
4. Brown ZA, Benedetti J, Ashley R, Burchett S, Selke S, Berry S, Vontver LA, Corey L.. 1991. Neonatal herpes simplex virus infection in relation to asymptomatic maternal infection at the time of labor. *N Engl J Med.* 324, 1247-1252
5. Brown, Z, S Sleke, J Zeh, J Kopelmann, A Maslow, R Ashley, D Watts, S Berry, M Herd, L Correy. 1997. The acquisition of herpes simplex virus during pregnancy. *N Engl J Med.* 337, 509-515
6. Bünzli, D, Wietlisbach V, Barazzoni F, Sahli R, Meylan PR. 2004. Seroepidemiology of Herpes Simplex virus type 1 and 2 in Western and Southern Switzerland in adults aged 25–74 in 1992–93 : a population-based study. *BMC Infect Dis.* 4. <http://www.biomedcentral.com/1471-2334/4/10>
7. CDC. 1998. Guidelines for Treatment of Sexually Transmitted Diseases. *MMWR.* 47, 1-118
8. Gerit Korr, Michael Thamm, Irina Czogiel, Christina Poethko-Mueller, Viviane Bremer and Klaus Jansen. 2017. Decreasing seroprevalence of herpes simplex virus type 1 and type 2 in Germany leaves many people susceptible to genital infection: time to raise awareness and enhance control. Korr et al. *BMC Infectious Diseases* (2017) 17:471
9. Prober, C, W Sullender, L Yasukawa, D Au, A Yaeger, A Arvin. 1987. Low risk if herpes simplex virus infections in neonates exposed to the virus at the time of vaginal delivery to mothers with recurrent herpes simplex virus infections. *N Engl J Med.* 316, 240-244
10. Rabenau HF, Buxbaum S, Preiser W, Weber B, Doerr HW. 2002. Seroprevalence of herpes simplex virus types 1 and type 2 in the Frankfurt am Main area, Germany. *Med Microbiol Immunol.* 190, 153-160
11. Roizman, B, DM Knipe. 2001. Herpes Simplex Viruses and Their Replication. . In Fields, B, D Knipe, P Howley, et al. (eds.). *Fields Virology* 4th Ed. Lippincott-Raven, Philadelphia
12. Smith J, N Robinson. 2002. Age-specific prevalence of infection with herpes simplex : a global review. *J Inf Dis.* 186, 3-28
13. Tunbäck, P, Bergström T, Claesson BA, Carlsson RM, Löwhagen GB. 2007. Early acquisition of herpes simplex virus type 1 antibodies in children-A longitudinal serological study. *J Clin Vir.* 40, 26-30
14. Whitley, R. 2001. Herpes Simplex Viruses. In Fields, B, D Knipe, P Howley, et al. (eds.). *Fields Virology* 4th Ed. Lippincott-Raven, Philadelphia
15. Wutzler, P, Doerr HW, Färber I, Eichhorn U, Helbig B, Sauerbrei A, Brandstädt A, Rabenau HF. 2000. Seroprevalence of herpes simplex virus type 1 and type 2 in selected German populations - relevance for the incidence of genital herpes. *J Med Virol.* 61, 201-207
16. Sauerbrei A. 2016. Herpes Genitalis: Diagnosis, treatment and Prevention. *Geburtshilfe Frauenheilkd.* 2016 Dec;76(12):1310-1317. doi: 10.1055/s-0042-116494. Epub 2016 Oct 18. Review.

Preparation of Patient Samples and Washing Solution

▼ **Washing Solution:** Fill up concentrate to 1 liter with aqua dest./demin.

▼ **IgG-Samples – Dilution**
1:101

e.g.:
10 µl serum/plasma + 1000 µl Dilution Buffer
(Serum Dilution Buffer is ready to use)

▼ **IgM-Samples - Dilution**
1:101

Absorption of Rheumatoid factor with RF-SorboTech

e.g.:
5 µl serum/plasma + 450 µl Dilution Buffer +
1 drop RF-SorboTech, incubate for 15 min. at room temperature.

Testprocedure

Samples Incubation **30 minutes at 37°C**



Wash 4times



Conjugate Incubation **30 minutes at 37°C**



Wash 4times



Substrate Incubation **30 minutes at 37°C**



Stopping



Measure
Extinctions

100 µl Patient Samples

blank value (Dilution Buffer) and controls

400 µl Washing Solution

Remove Residues on a Cellulose Pad

100 µl Conjugate

IgG, IgM

400 µl Washing Solution

Remove Residues on a Cellulose Pad

100 µl Substrate

50 µl Stopping Solution

shake carefully

Photometer at 450/620nm
(Reference Wavelength 620-690nm)